Objective To describe a case of acute visual loss due to retinal arteriolar embolization caused by transeptal triamcinolone-acetonide injection, with rapid visual recovery following immediate intervention. Methods This is a case report. Results A 39-year-old female developed loss of vision (no light perception) after transeptal triamcinolone-acetonide injection. Examination revealed yellowish, particulate emboli within the retinal arterioles. Strategies to relieve the obstructed vessel (anterior-chamber paracentesis, intraocular-pressurelowering medications, and ocular massage) were immediately performed. Full recovery of vision occurred within 24 hours. Conclusion Retinal vascular embolization should be suspected when there is loss of vision after corticosteroid injection. Immediate ocular decompression may lead to rapid improvement and favorable visual outcomes.

Objective: To describe a case of inflammatory pigment epithelial detachment (PED) presumed to be secondary to the amoeba Blastocystis hominis. Methods: This is an interventional case report. Results: A 46-year-old male complained of visual distortion in the left eye for 7 months. Examination revealed the presence of a subretinal cystic lesion on the fovea. Optical coherence tomography demonstrated a PED with a hyperreflective lesion over the detached retinal pigment epithelium (RPE). Work-up included a fecalysis, which revealed the presence of Blastocystis hominis. The patient was treated with oral metronidazole. RPE detachment resolved after treatment with no recurrence in 30 months of follow-up. Conclusion Intestinal parasitic infection may be associated with retinal disease and should be included in the differential diagnosis of PED when OCT reveals a hyperreflective lesion.
Blastocystis hominis

Objective: To report the efficacy and safety of intravitreal pegaptanib sodium (IVP) on macular edema (ME) due to branch retinal-vein occlusion (BRVO) among patients intolerant to intravitreal triamcinolone acetonide (IVTA). Methods: Four eyes with ME due to BRVO were included in this interventional case series. The main outcome measures were best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and adverse effects. Results: There was a significant decrease in mean CMT from 524.50 ± 141.12 to 293.75 ± 130.75 microns (p = 0.009) after IVP injection. BCVA improved in all 4 eyes after IVP. Mean IOP after IVP was 13.60 ± 3.21. No ocular or systemic complications were observed. Conclusion IVP appears to be safe and effective in decreasing retinal thickness and improving VA in eyes with ME due to BRVO. IVP is a potential treatment for eyes that are intolerant to IVTA.
Macular Edema